Novo Nordisk signed a partnership worth up to $2.1 billion with Vivtex to develop oral treatments for obesity and diabetes.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results